Evaluation of the tolerability of the dornase alfa based on the results of a multicenter scientific program of post-marketing use of the medicine

Conclusions: The Tigeraza® (Generium, Russia) was well tolerated by patients with CF in 93.4% of cases and the frequency of ADRs were less than 1: 1000, which did not exceed the frequency of ADRs with the use of the Pulmozyme® (F. Hoffmann-La Roche Ltd., Switzerland).

Source: European Respiratory Journal - November 25, 2021 Category: Respiratory Medicine Authors: Kondratyeva, E., Shadrina, V., Furman, E., Voronkova, A., Sherman, V., Zhekaite, E., Simanova, O., Malakhov, A., Mukhina, M., Yakushina, E., Vysokolova, O., Ilyenkova, N., Trishina, S., Pinegina, J., Safonova, T., Vasilyeva, E., Golubtsova, O. Tags: Adult cystic fibrosis (CF) Source Type: research